The FDA approved Metreleptin injection for treating complications of leptin deficiency in February 2014.In a three-year study of metreleptin in patients with lipodystrophy organized by the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, metreleptin treatment was associated with a significant decrease in blood glucose (A1c decreased from 9.4% at baseline to 7.0% at study end) and triglyceride concentration (from 500 mg/dl at baseline to 200 mg/dl at study end). Metreleptin is effective in most patients with generalized lipodystrophy where circulating leptin levels are extremely low. Analogous to insulin replacement for patients with type 1 Diabetes, metreleptin restores the function of a deficient hormone. However, in patients with partial lipodystrophy where there is only a relative leptin deficiency, the response to metreleptin is not universal. This may or may not be due to anti-leptin antibodies. NHS England will commission metreleptin treatment for patients (all ages) with congenital leptin deficiency from April 1, 2019. References
External links
"Metreleptin". Drug Information Portal. U.S. National Library of Medicine.
Five-dimensional and every higher dimension: three regular convex 
  
    
      
        n
      
    
    {\displaystyle n}
  -polytopes, all within the infinite family of regular 
  
    
      
        n
      
    
    {\displaystyle n}
  -simplexes, 
  
    
      
        n
      
    
    {\displaystyle n}
  -hypercubes, and 
  
    
      
        n
      
    
    {\displaystyle n}
  -orthoplexes.The fourth dimension is also the highest dimension where regular self-intersecting figures exist:

Two-dimensional: infinitaly many regular star polygons. Three-dimensional: four regular star polyhedra, the regular Kepler-Poinsot star polyhedra. Four-dimensional: ten regular star polychora, the Schläfli–Hess star polychora. They contain cells of Kepler-Poinsot polyhedra alongside regular tetrahedra, icosahedra and dodecahedra.